Urgent care near me 
Wegovy pill from $149/month
The FDA-approved weight loss pill is here
No injections. Just once-daily Wegovy® with proven results—up to 17% average weight loss in trials.
Key points
- The two most effective FDA-approved weight loss injections are Wegovy (semaglutide, ~15% body weight loss) and Zepbound (tirzepatide, ~21% body weight loss) — both given as weekly injections.
- GLP-1 receptor agonists work by slowing gastric emptying, reducing appetite signals in the brain, and improving insulin response — making you feel full longer and eat less.
- The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to improve over time and are minimized by starting at low doses.
- FDA-approved indications require a BMI ≥ 30, or BMI ≥ 27 with a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
- List prices run $1,000–$1,400/month without insurance. Coverage varies widely — check with your insurer and prescriber, as manufacturer savings programs may reduce out-of-pocket costs.
The FDA-approved weight loss pill is here
[toc]
Weight loss injections — most of which belong to a drug class called GLP-1 receptor agonists — have become one of the most effective tools available for chronic weight management. These medications work by mimicking gut hormones that regulate appetite and blood sugar, helping people eat less and lose weight more reliably than lifestyle changes alone.1
This article covers the FDA-approved options, how they work, how well they perform, their side effects, and what to expect if you're considering one.
FDA-approved weight loss injections
Semaglutide (Wegovy)
Wegovy is a GLP-1 receptor agonist approved by the FDA in 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.2 It is injected once weekly. In the STEP 1 clinical trial, participants lost an average of 14.9% of body weight over 68 weeks — approximately three times more than those on placebo.3
In 2024, the FDA also approved Wegovy to reduce the risk of serious cardiovascular events in adults with obesity or overweight and established cardiovascular disease — the first weight loss medication approved for this indication.2
Tirzepatide (Zepbound)
Zepbound, approved by the FDA in November 2023, is a dual GIP/GLP-1 receptor agonist — the first in its class approved for weight management.2 It is injected once weekly. In the SURMOUNT-1 trial, participants lost an average of 20.9% of body weight over 72 weeks at the highest dose, outperforming semaglutide in head-to-head trials.4
Liraglutide (Saxenda)
Saxenda was the first GLP-1 injectable approved for weight management (2014) and is administered as a daily injection. Clinical trials showed average weight loss of 8–10% of body weight over one year.5 It is less commonly prescribed now that weekly options with stronger efficacy data are available, but remains an approved option.
Semaglutide (Ozempic) and tirzepatide (Mounjaro) — off-label use
Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes management. They are widely prescribed off-label for weight loss and use the same active ingredients as Wegovy and Zepbound, respectively, but at slightly different dosing protocols. A healthcare provider can advise whether an on-label or off-label option is appropriate for your situation.
How do GLP-1 weight loss injections work?
GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, a hormone released by the gut after eating. They work by:1
- Slowing gastric emptying, so you feel full longer
- Reducing appetite signals in the brain
- Stimulating insulin release in response to meals (relevant for patients with type 2 diabetes)
Tirzepatide also activates GIP receptors, which appear to enhance fat metabolism — explaining its higher average weight loss compared to GLP-1-only agents.
How quickly do weight loss injections work?
Most people begin to notice appetite changes and early weight loss within the first four to eight weeks. However, maximum weight loss typically occurs over 12 to 18 months of treatment. Clinical trials show:3,4
- Wegovy (semaglutide): ~15% average body weight loss over 68 weeks
- Zepbound (tirzepatide): ~21% average body weight loss over 72 weeks (highest dose)
- Saxenda (liraglutide): ~8–10% average body weight loss over 56 weeks
Weight loss varies significantly by individual based on adherence, diet, activity level, and biological factors.
Side effects of weight loss injections
The most common side effects of GLP-1 receptor agonists are gastrointestinal and tend to be most pronounced when doses are increased:1,5
- Nausea (most common, especially early in treatment)
- Vomiting
- Diarrhea or constipation
- Abdominal pain or discomfort
- Injection site reactions (redness, bruising)
Less common but more serious potential side effects include pancreatitis, gallbladder problems, and — based on animal studies — a possible risk of thyroid C-cell tumors (a contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome). Discuss your full medical history with a prescriber before starting.1
GI side effects often improve over time and can be minimized by starting at low doses and increasing gradually.
Who is a candidate for weight loss injections?
FDA-approved indications for Wegovy and Zepbound require:2
- BMI ≥ 30 (obesity), or
- BMI ≥ 27 (overweight) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol
These medications are intended as part of a comprehensive weight management program that includes a reduced-calorie diet and increased physical activity. They are not appropriate for everyone — a prescriber will review your medical history, current medications, and weight loss goals before prescribing.
How much do weight loss injections cost?
List prices for Wegovy and Zepbound are roughly $1,000–$1,400 per month without insurance. Insurance coverage varies widely — some commercial plans cover these medications for indicated patients, while many do not, and Medicare coverage has been limited. Manufacturer savings programs and compounding pharmacies (for off-patent formulations) have expanded access for some patients, though compounded semaglutide carries regulatory and quality caveats. Check with your insurer and prescriber for current coverage and cost options.
Frequently asked questions
What is the most effective weight loss injection available?
Zepbound (tirzepatide) has shown the highest average weight loss in clinical trials — approximately 21% of body weight over 72 weeks. Wegovy (semaglutide) produced about 15% average weight loss over 68 weeks. Both are significantly more effective than older options like Saxenda (liraglutide) at ~8–10%.
How long do you stay on weight loss injections?
Most clinical trials run 68–72 weeks, but these medications are intended for long-term use. Weight tends to return when the medication is stopped, so many people continue treatment indefinitely as part of ongoing weight management. Discuss the appropriate duration with your prescriber.
Can you get weight loss injections at urgent care?
Some urgent care clinics and telehealth providers offer GLP-1 prescriptions, though evaluation requirements vary. A prescriber must review your BMI, medical history, current medications, and eligibility criteria before prescribing. If you're interested, search for clinics that offer medical weight loss services near you.
What are the most common side effects of weight loss injections?
The most common side effects are nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These are most pronounced when starting the medication or increasing the dose, and typically improve over time. Starting at a low dose and increasing gradually helps minimize GI side effects.
Is Ozempic the same as Wegovy?
Both Ozempic and Wegovy contain semaglutide, but they are approved for different indications. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved specifically for chronic weight management at a higher maximum dose. Ozempic is frequently prescribed off-label for weight loss, but Wegovy is the on-label option.
Who should not take weight loss injections?
GLP-1 medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). They are generally not recommended during pregnancy. People with a history of pancreatitis or gallbladder disease should discuss risks carefully with their prescriber.
See if you qualify
How we reviewed this article
Medically reviewed
View this article's sources and history, and read more about Solv's Content Mission Statement, editorial process, and editorial team.
5 sources
Solv has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical associations. We avoid using tertiary references.
- Müller TD, Blüher M, Tschöp MH, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery. 2022;21(3):201–223.
- U.S. Food and Drug Administration. FDA approves new medication for chronic weight management. fda.gov. Accessed May 2026.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989–1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015;373(1):11–22.
Solv’s team of medical writers and experts review and update our articles when new information becomes available.
September 11 2024
Written by Solv Editorial Team
Medically reviewed by: Dr. Rob Rohatsch, MD
May 06 2026
Edited by Solv Editorial Team
May 20 2026
Edited by Solv Editorial Team
May 23 2026
Edited by Solv Editorial Team
